正在加载公司
截至 2026年9月30日 的季度，与去年同季度相比。
Quest Diagnostics Inc.’s own guidance, from its results release of 2026年10月22日. It is the company’s statement of what it expects, not a forecast of ours.
| 指标 | 截至该日的 3 个月2026年9月30日 | 截至该日的 3 个月2025年9月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$3.1B | US$2.8B | +9.98% |
| 利润 | US$312M | US$245M | +27.35% |
| 每股收益 | US$2.78 | US$2.16 | +28.70% |
| 自由现金流 | US$445M | US$419M | +6.21% |
这些是单季度数字，不是滚动一年——本站其他地方的数字覆盖十二个月，会大得多。季节性业务在两者之间摆动很大：ServiceNow 在十二月季度赚 20 亿美元自由现金流，在六月季度只有 5 亿。
对比对象是去年同一季度，而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据，那是我们没有的授权数据——而搞错它比不提更糟。
每场电话会的简短摘要——本季度的表现、管理层的预期，以及他们是否兑现了上次所说的话——下方附完整文字记录。
“) of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025 • Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion • Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35 SECAUCUS, N.J., October 22, 2026 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026. “We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI,”
逐字引自公告，且只在文件将其归于具名人士时才展示。
公告在开盘前或收盘后发布，因此区间从公告日前一个交易日的收盘价到公告日之后那个交易日的收盘价——无论哪种情况，反应都包含在内。
Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.
公司自己的描述，取自公告末尾。
引述和公司简介来自 Quest Diagnostics Inc. 于 2026年10月22日 提交的第 2.02 项 8-K 文件；表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。
Quest Diagnostics performs medical tests on blood and other samples for doctors, hospitals, health plans and patients.
公司指引：2026 财年营收 US$12.1B 至 US$12.1B — 同比增长 9.5%
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
此前电话会的摘要属于 Pro 内容。
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
电话会摘要属于 Pro 内容
两分钟读完 Quest Diagnostics Inc. 的每场业绩电话会：关键数字、管理层的预期、是否兑现了上季度的展望，以及分析师提出但未获回答的问题。
先在 , , , 或 上看一份——向所有人开放。
此前电话会的摘要属于 Pro 内容。 了解 Pro
此前电话会的摘要属于 Pro 内容。 了解 Pro
Results released 2026年10月22日, before the market closed
Raised full-year guidance and strong test volumes likely outweighed falling revenue per requisition and a newly disclosed patient-records cyber incident.
Into the report: +2.2% over a month, +5.2% over three months, -3.1% from the year's high.
What the full-year guide leaves · Adjusted diluted EPS
Like for like: No change in the adjusted-EPS definition is identified; the FY2026 adjusted midpoint is $11.30 versus the prior FY2026 guide of $11.15.
Written by AI on 2026年10月23日 from Quest Diagnostics Inc.'s results releases, earnings call and SEC filings; every quote it relied on was checked against them. It describes the report, it is not investment advice, and it is in English only.
